Adaptimmune Therapeutics Receives Orphan Drug Designation

- September 9th, 2019

Adaptimmune Therapeutics (NASDAQ:ADAP) has announced that the US Food and Drug Administration (FDA) has granted it orphan drug designation for its SPEAR T-cells targeting MAGE-A4 to treat soft tissue sarcomas. As quoted in the press release:  Orphan Designation by FDA was created to encourage the development of drugs for rare diseases, such as sarcomas. “We … Continued

Adaptimmune Therapeutics (NASDAQ:ADAP) has announced that the US Food and Drug Administration (FDA) has granted it orphan drug designation for its SPEAR T-cells targeting MAGE-A4 to treat soft tissue sarcomas.

As quoted in the press release:

 Orphan Designation by FDA was created to encourage the development of drugs for rare diseases, such as sarcomas.

“We recently started SPEARHEAD-1 treating patients with synovial sarcoma and myxoid/round cell liposarcoma (MRCLS), with the aim to launch ADP-A2M4 in 2022,” said Elliot Norry, Adaptimmune’s interim Chief Medical Officer. “This orphan drug status is another key milestone in achieving our goal of providing this much-needed therapy to people living with these rare and deadly cancers, for which there are few other treatment options.”

Click here to read the full press release.

  Life Science and Healthcare Investing in 2020 report cover

Life Science and Healthcare Investing in 2020

 
The life science and healthcare market is a booming, multi-billion dollar industry. Read our 2020 life science outlook report!
 

 

Get the latest Biotech Investing stock information

Get the latest information about companies associated with Biotech Investing Delivered directly to your inbox.

Biotech Investing

Select None
Select All

Leave a Reply